

ProBioGen Signed Agreement on Testing of Neuronal Cell Lines with Serono.

Berlin, 5th April 2006 – ProBioGen AG announced today that Serono S.A., Switzerland has signed an Agreement to evaluate ProBioGen's novel human neuronal cell line for the production of recombinant proteins.

Under the terms of the Agreement, Serono will explore the feasibility of using the proprietary neuronal cell line of ProBioGen as a host for the production of recombinant proteins. Financial details are not disclosed.

“Our human neuronal cell lines not only have the advantage of producing proteins with human glycosylation patterns, but they also have been developed with a fully documented history, a very important prerequisite for smooth approval of products derived from a cell line,” said Michael Schlenk, CEO of ProBioGen AG. “In addition, they have a very high productivity, so we think we have created cell lines that can produce human biopharmaceuticals very cost effectively and with a very high safety profile. We are very glad that we won Serono as the first partner to explore the huge potential of these cell lines as Serono has a lot of experience in developing recombinant proteins.”

About ProBioGen AG

ProBioGen AG is a specialist for cell line design, viral vectors, and the manufacture of glycoproteins for the biopharmaceutical industry. Its range of products and services includes the design of novel cell lines from primary tissue, the development of highly productive mammalian cell lines, as well as the manufacture of glycoproteins for clinical studies. ProBioGen possesses the manufacturing authorization for pharmaceutically usable active substances for testing in clinical studies and meets the quality standards recommended by the EU (EMA) and the FDA. A certified cGMP multipurpose facility is available for the contract production of biopharmaceutical active substances. The company combines the know-how of molecular biology scientists with the experience of experts in cell culture technology and process engineering. ProBioGen accompanies its clients through all stages, from the development of product candidates to the clinical testing phase.

ProBioGen Contact

*Michael Schlenk
Goethestraße 54
13068 Berlin
Tel.: +49.30.924006-147
Fax: +49.30.924006-19
e-mail: michael.schlenk@probiogen.de*